Cardiovascular side effects of atomoxetine and its interactions with inhibitors of the cytochrome p450 system

Pashtoon Murtaza Kasi, Rawad Mounzer, George H. Gleeson

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Attention deficit hyperactivity disorder (ADHD) is one of the most common neurobehavioral disorders of childhood and adolescence. Classically, stimulants have been used in the treatment of this condition. Atomoxetine (Strattera; Eli Lilly and Company) is a selective norepinephrine reuptake inhibitor (SNRI), one of the first medications in the nonstimulant class of medications that has been approved by the FDA for the treatment of ADHD. Atomoxetine is a phenoxypropylamine derivative and is structurally related to the antidepressant fluoxetine. The common side effects reported with the use of atomoxetine include mainly GI disturbances. Cardiovascular side effects are less commonly reported. The increase in the noradrenergic tone may explain some of the side effects noted with the use of this medication. Here, we present a case of a patient who presented with syncope, orthostatic hypotension, and tachycardia and discuss the various clinical implications based on the pharmacokinetics and pharmacodynamics of the drug.

Original languageEnglish (US)
Article number952584
JournalCase Reports in Medicine
Volume2011
DOIs
StatePublished - 2011

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Cardiovascular side effects of atomoxetine and its interactions with inhibitors of the cytochrome p450 system'. Together they form a unique fingerprint.

  • Cite this